最後更新：2026年10月1日
腫瘤疼痛是惡性腫瘤患者常見的嚴重臨床問題，可由腫瘤直接侵犯（骨骼、神經、內臟）或治療相關因素引起。WHO 疼痛階梯為管理框架。維持生活品質是腫瘤疼痛管理的核心目標。。病理機制涉及組織細胞層面的損傷和免疫反應。
貓的疾病表現常較犬隱匿，需注意細微行為變化
可點的項目會開啟該疾病頁。要依症狀與檢驗排出完整清單，請用鑑別診斷工具。
丁基原啡因。Analgesic
納布啡。Opioid analgesic (Agonist-antagonist)
加巴噴丁。Gabapentinoid (Anticonvulsant / Analgesic)
建議：依臨床狀況調整
| 藥物 | 劑量 | 頻率 | 路徑 | 優先級 |
|---|---|---|---|---|
| Buprenorphine Hydrochloride 丁基原啡因。Analgesic | 犬 0.01-0.02 mg/kg q6-12h IV/IM；貓 0.01-0.03 mg/kg q6-12h IV/IM | Q6-12H | IV | 首選 |
| Nalbuphine 納布啡。Opioid analgesic (Agonist-antagonist) | 犬 0.1-0.5 mg/kg q4-6h IV/IM/SC；貓 0.05-0.2 mg/kg q4-6h IV/IM/SC | Q4-6H | IV | 首選 |
| 藥物 | 劑量 | 頻率 | 優先級 |
|---|---|---|---|
| Co-danthramer, Co-danthrusate 丹蒽醌複方。Antibacterial | 犬 10-20 mg/kg q12h PO；貓 10-15 mg/kg q12h PO | Q12H | 首選 |
| Gabapentin 加巴噴丁。Gabapentinoid (Anticonvulsant / Analgesic) | 犬 5-10 mg/kg q8-12h PO；貓 5-10 mg/kg q8-12h PO | Q8-12H | 首選 |
監測頻率：依病因
[1]Pain Management in Animals with Oncological Disease: Opioids as Influencers of Immune and Tumor Cellular Balance.
[2]Resiniferatoxin: Nature's Precision Medicine to Silence TRPV1-Positive Afferents.
[3]Wnt Signaling Pathways: A Role in Pain Processing.
[4]Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials.
[5]Opioids: Modulators of angiogenesis in wound healing and cancer.
穩定但需注意惡化徵兆，建議安排近期門診 (stable but monitor for deterioration, schedule near-term visit)
疼痛管理可顯著改善腫瘤患者生活品質。多模式止痛效果優於單一藥物。需隨疾病進展調整方案。
Diagnostic Approach for Cancer Pain
Thorough history collection; complete physical examination with attention to presenting complaint
CBC, serum chemistry panel, urinalysis; additional tests based on clinical findings
Advanced imaging, specialized testing, or referral based on minimum database findings